AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Jonah Keri
Allergan has traded in a tight base, mostly between 75 and 80, for the last 12 weeks. The stock has straddled its 50-day moving average during that time, and currently sits above that line. It's 2% off its high.
With leading stocks surging to new highs, Allergan's flat chart pattern earns the stock a lukewarm 62 Relative Price Strength Rating.
The maker of eye care and skin care products, including Botox, fares better fundamentally, scoring an A- Fundamental Rating from the IBD Stock Checkup. Botox provided much of that strength, netting nearly a third of the firm's $1.39 billion in sales last year, with analysts expecting ...